Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced their participation in the 35th Annual Piper Sandler Healthcare Conference in New York. CEO Mark Erlander will be presenting at the fireside chat on 11/29/2023, discussing the company's innovative PLK1 inhibition therapies for cancer. Interested parties can register for the live webcast on the Cardiff Oncology website.

SAN DIEGO, Nov. 20, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 35th Annual Piper Sandler Healthcare Conference, which is taking place at the Lotte New York Palace in New York from November 28-30, 2023.

Details of the fireside chat can be found below.

Presenter: Mark Erlander, CEO
Date: 11/29/2023
Time: 10:00 – 10:25 AM ET in Soho Track

Interested parties can register for and access the live webcast for Piper Sandler by visiting the "Events" section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com

Investor Contact:
Kiki Patel, PharmD 
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com

Media Contact:
Richa Kumari
Taft Communications
551 344-5592 
richa@taftcommunications.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-the-35th-annual-piper-sandler-healthcare-conference-301991867.html

SOURCE Cardiff Oncology, Inc.

FAQ

What is Cardiff Oncology, Inc. participating in?

Cardiff Oncology, Inc. is participating in the 35th Annual Piper Sandler Healthcare Conference in New York.

Who will be presenting at the fireside chat?

CEO Mark Erlander will be presenting at the fireside chat.

What will be discussed at the fireside chat?

The discussion will focus on Cardiff Oncology's PLK1 inhibition therapies for cancer.

Where can interested parties register for the live webcast?

Interested parties can register for the live webcast on the Cardiff Oncology website.